HZNP

Horizon Therapeutics Public Limited Company

A biopharmaceutical company that develops and sells medicines for rare, autoimmune, and severe inflammatory diseases, including Krystexxa for chronic gout and Tepezza for thyroid eye disease. Founded in 2005 in Illinois as Horizon Pharma, it merged with Swiss drugmaker Nitec Pharma in 2010 and was bought by Amgen in 2023. Its gout drug Krystexxa earned fame for literally "melting" away the painful uric-acid crystals that disfigure severe gout patients.

No 8-K or 6-K filings recorded.